A Look at Emerging Healthcare Innovations From a Veteran Investor- Gurdane Bhutani, Managing Partner & Co-Founder at MBX Capital

“The unifying theme across our portfolio is that whatever a company we invest in is building can make a population-level health impact. For us, that means that what they're doing is going to lead to innovation that is ultimately accessible to huge portions of the global population,” says Gurdane Bhutani, co-founder and managing partner of MBX Capital, a venture capital partnership dedicated to investing in early-stage companies focused on big public health problems. As he explains to host Shiv Gaglani, that ambitious mission is focused on three main themes: accumulated environmental exposure (exposome), biosecurity and biodefense, and healthcare infrastructure. “The majority of disease pathogenesis today is environmental in nature, not genetic. So we're looking at companies that are developing exposomic sequencing technologies that help us better understand these environmental exposures.” One such company is using human-relevant tissue models to test for environmental contaminants. Others include a nurse scheduling platform and a firm that’s localizing radiology systems for underdeveloped areas. Bhutani has a track record of investing in interesting and impactful companies in healthcare (in fact, he was an early backer of Osmosis!) so you won’t want to miss his insightful perspective on promising ideas for improving health and healthcare systems.

Mentioned in this episode: https://www.mbxcapital.com/

If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast